← Back to Search
Inflammation In Atherosclerosis And Implications For Therapy
R. Paoletti, A. Gotto, D. Hajjar
Published 2004 · Medicine
Download PDFAnalyze on Scholarcy
Atherosclerosis is now understood to be a disease characterized by inflammation that results in a host of complications, including ischemia, acute coronary syndromes (unstable angina pectoris and myocardial infarction), and stroke. Inflammation may be caused by a response to oxidized low-density lipoproteins, chronic infection, or other factors; and markers of this process, such as C-reactive protein, may be useful to predict an increased risk of coronary heart disease. Thus, we believe that inflammatory processes may be potential targets of therapy in preventing or treating atherosclerosis and its complications.
This paper references
High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection
BJ Van Lenten (2001)
The role of high-density lipoproteins in oxidation and inflammation.
B. V. Van Lenten (2001)
Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
PM Ridker (1998)
Plaque disruption and thrombosis. Potential role of inflammation and infection.
P. Shah (1999)
Lipoprotein Trafficking in Vascular Cells
D. Hajjar (1997)
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
J. Gómez-Gerique (2002)
Blood levels of long-chain n-3 fatty acids and the risk of sudden death.
C. Albert (2002)
Predisposition to Atherosclerosis by Infections: Role of Endothelial Dysfunction
A. Prasad (2002)
for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
Pm Ridker (1998)
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
M. Hernández-Presa (2002)
Circulating Oxidized Low Density Lipoprotein Levels: A Biochemical Risk Marker for Coronary Heart Disease
S. Toshima (2000)
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
P. Ridker (2001)
HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.
M. Navab (2001)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
P. Ridker (2001)
Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box?
B. Molavi (2002)
Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure
U. Jorde (2002)
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P. Ridker (1997)
Sol Sherry Lecture in Thrombosis: Molecular Events in Acute Inflammation
S. Prescott (2002)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
P. Ridker (1998)
Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age.
M. Gattone (2001)
Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network
D. Hajjar (1992)
Atherosclerosis and inflammation.
I. Joris (1978)
Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation.
A. Bloodsworth (2000)
Inflammation and Atherosclerosis
S. Steffens (2004)
Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?
D. Steinberg (2002)
High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study
S. Kinlay (2003)
High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease.
W. Speidl (2002)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
S. Grundy (2002)
Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels
I. Jialal (2001)
Molecular events in acute inflammation
SM Prescott (2002)
High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection
B. V. Van Lenten (2001)
Fatty acid modulation of endothelial activation.
R. De Caterina (2000)
C-reactive protein, inflammation, and innate immunity
R. Mortensen (2001)
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness
A. Taylor (2002)
for the West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease
Cj Packard (2000)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
C. Packard (2000)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
S. Yusuf (2002)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
G. Schwartz (2001)
Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
M. Burleigh (2002)
PERMANENT PIGMENTATION FOLLOWING APPLICATION OF IRON SALTS: FOR THE TREATMENT OF IVY POISONING
E. F. Traub (1936)
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
J. Danesh (2000)
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
A. Halkin (2002)
Interleukin‐6 and acute coronary syndrome
U. Ikeda (2001)
Effects of simvastatin and atorvastatin on inflammation markers in plasma
O. Wiklund (2002)
Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction
Julie K. Plenge (2002)
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
M. Albert (2001)
Transforming growth factor-beta up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells.
A. C. Nicholson (1992)
Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection.
A. Carr (2000)
Inflammation and atherosclerosis. Circulation
P Libby (2002)
C-reactive protein--to screen or not to screen?
L. Mosca (2002)
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
S. Grundy (2002)
Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes
S. Ehara (2001)
Atherosclerosis--an inflammatory disease.
Kenny J. Williams (1999)
Fish and omega-3 fatty acid intake and risk of coronary heart disease in women.
F. Hu (2002)
Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22.
T. Pantoja (2003)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
A. Coats (2002)
This paper is referenced by
Anti-inflammatory Effect of Hydroalcoholic Extract of the Washingtonia filifera Seeds in Carrageenan-Induced Paw Edema in Rats
A. Hemmati (2015)
Effect of Chinese herbal medicine for activating blood circulation and detoxifying on expression of inflammatory reaction and tissue damage related factors in experimental carotid artery thrombosis rats
Mei Xue (2010)
The Association Between Hay Fever and Stroke in a Cohort of Middle Aged and Elderly Adults
E. Matheson (2008)
Study of the Correlation between high sensitivity C reactive protein and Each of Malondialdehyde , Lipid profile, and Atherogenic Index inPatients with Ischemic Heart Diseases(IHD) in Thi-Qar Governorate
[Histopathological examination and analysis of mortality in DBA/2 mouse vasculitis induced with CAWS, a water-soluble extracellular polysaccharide fraction obtained from Candida albicans].
Naoto Hirata (2006)
Simvastatin attenuates the lipopolysaccharideinduced inflammatory response of rat pulmonary microvascular endothelial cells by downregulating toll-like receptor 4 expression
Yi Li (2014)
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
W. Insull (2009)
Insulin resistance and oxidative stress in familial combined hyperlipidemia.
S. Martínez-Hervás (2008)
Acute respiratory tract infections: A potential trigger for the acute coronary syndrome
R. Harskamp (2008)
Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life.
C. Militaru (2013)
Restoring Immune Tolerance in Atherosclerosis: Role of Regulatory Immune Response in Atheroprotection.
Lakshmi A Mundkur (2015)
Inflammation-Angiogenesis Cross-Talk and Endothelial Progenitor Cells: A Crucial Axis in Regenerating Vessels
M. Ciulla (2011)
Cardiovascular sequelae of tobacco smoking.
Kenneth J. Rempher (2006)
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control
N. Merchant (2012)
Cytomegalovirus Infection and Coronary Artery Disease: A Single- Center Serological Study in Northwestern Iran
Z. R. Khameneh (2016)
Cytomegalovirus in coronary heart disease.
P. Tornvall (2006)
Statin Therapy Decreased the Recurrence Frequency of Atrial Fibrillation after Electrical Cardioversion: A Meta-Analysis
P. Yan (2014)
Potentiation of indomethacin-induced anti-inflammatory response by montelukast in formalin-induced inflammation in rats.
A. Hemmati (2013)
Effets cliniques à court terme des statines initiées avant une intervention
P. Ambrosi (2013)
Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study
A. Spirou (2006)
Understanding the role of MasR in vascular pathology
S. Rai (2016)
Premature subclinical atherosclerosis in pediatric inflammatory bowel disease.
M. Aloi (2012)
RISCO DE APNEIA OBSTRUTIVA DO SONO DETECTADO PELO QUESTIONÁRIO DE BERLIM ESTÁ ASSOCIADO COM ATEROSCLEROSE CORONARIANA.
Cardiologia E Ciências (2010)
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function
B. Khan (2011)
Targeting heme oxygenase-1 in the treatment of atherosclerosis
W. Durante (2005)
Helicobacter Pylori Induces GATA3-Dependent Chitinase 3 Like 1 (CHI3L1) Upregulation and Contributes to Vascular Endothelial Injuries
Jingshu Chi (2019)
C-Reactive Protein and the Framingham Coronary Risk Score in Patients Newly Diagnosed With Intermittent Claudication
Y. Shahin (2012)
Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness.
K. M. Choi (2009)
Identifying sm22 as a key player in arterial diseases
Jianbin Shen (2012)
Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability.
E. J. Wasserman (2006)
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
D. B. Kell (2008)
Intraluminal Carotid Artery Thrombus in COVID-19: Another Danger of Cytokine Storm?
A. Mohamud (2020)See more